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This forum report contains conclusions about 3 different issues relevant to conducting clinical trials in deep
mycoses. (1) Trials of diagnostic tests for deep mycoses must define the population appropriate for testing
and the clinical question being asked. The unanswered question for the serum Aspergillus galactomannan
assay is whether knowledge of results can change use of empirical therapy to treat febrile patients at high
risk of invasive aspergillosis. (2) Use of historical controls is suboptimal but offers a pragmatic solution for
studying rare mycoses; use of contemporaneous controls, matched for critical variables and evaluated by a
blinded data review committee using detailed criteria, appears optimal. (3) Established groups of independent
investigators, such as the European Organization for Research on Treatment of Cancer’s Invasive Fungal
Infections Group and National Institute of Allergy and Infectious Diseases’s Bacteriology and Mycology Study
Group, provide a pool of experienced investigators, defined operating rules, impartiality, and specialized
expertise. Considering the enormous investment required for adequately powered efficacy trials of antifungal
agents and the importance of these trials to guide clinical practice, use of collaborative groups outweighs the
extra administrative time that is sometimes required.
ISSUES IN TRIALS OF DIAGNOSTIC
TESTS
The sandwich ELISA (Platelia; BioRad) for detection
of Aspergillus galactomannan antigen in patient serum
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was taken as a case study for the discussion on the
design of diagnostic trials because of its clinical rele-
vance to the other topics under discussion at the John
E. Bennett Forum on Deep Mycoses Study Design. The
members of the Forum used the studies by Maertens
et al. [1] and Herbrecht et al. [2] as models for the
discussion.
General principles for analysis of diagnostic tests.
Four numbers encompass the simplest results of a di-
agnostic test. A tally is made of the patients with or
without the diagnosis who have a positive or negative
test result. Sensitivity and specificity use the 4 numbers
to pose the question in a manner that assumes that the
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diagnosis is already known and asks the percentage of patients
with the diagnosis for whom the test result was correctly pos-
itive (sensitivity) and the percentage without that diagnosis for
whom the test result was correctly negative (specificity). Positive
and negative predictive values look at the same 4 numbers but
assume that the test result is known and ask whether the test
correctly predicted the diagnosis. Both kinds of analysis require
that an intermediate or indeterminate result is either excluded
or reclassified as positive or negative. Both analyses assume that
the cutoff separating categories has already been decided. Often
the cutoff is not obvious and is decided as a compromise be-
tween sensitivity and specificity. A receiver operating curve
(ROC) can help decide the optimal cutoff. The ROC plots rates
of true-positive (sensitivity) versus false-positive (1– specificity)
results at different cutoffs. The clinical implications of false-
negative and false-positive results weigh heavily in estimating
the impact of different cutoffs. The appearance of the ROC
and choice of optimal cutoff will vary with the incidence of
disease in the population under study (pretest probability). The
principles elucidated above will be applied to the serum As-
pergillus galactomannan ELISA.
Clinical results of galactomannan testing. The galacto-
mannan ELISA results are reported as a ratio between the op-
tical density of the patient’s sample and that of a control with
a low but detectable amount of galactomannan. The manu-
facturer considers a ratio 11.5 to be positive, a ratio of 1.0–1.5
intermediate, and a ratio !1.0 negative. The reported results
with the galactomannan ELISA have depended on several var-
iables: the degree of severity of the patients’ aspergillosis at time
of diagnosis, the prevalence of aspergillosis among the patients
studied, the cutoff ratio used, and whether two consecutive
positive tests were required for significance. Also, age has been
important because more false-positive results have been found
among young children [2]. In a patient population with a high
incidence of aspergillosis, 71 autopsy-proven cases, a cutoff
ratio of 1.5, and a requirement for 2 consecutive positive tests,
the test had a sensitivity of almost 93% and specificity of 95%
[1]. In a study of adults and children with less definite and less
fatal disease, a lower prevalence of aspergillosis, and a single
test with a cutoff ratio of 1.5, sensitivity was 28% (40/145
episodes) and specificity was 99% [2]). As these examples show,
performance of the galactomannan test has depended critically
on the population under study and appears most appropriate
for patients with a high pretest probability of having the
diagnosis.
Posing the clinical questions for future analyses. Another
way to examine this diagnostic test is to identify the clinical
questions that the test seeks to answer. In a patient with a high
pretest probability of disease, such as an allogeneic hemato-
poietic stem cell transplant recipient with pulmonary infiltrate
not responding to current antifungal therapy, the clinical ques-
tion is whether to switch to, or add, another antifungal agent
that would be useful to treat aspergillosis but not other molds.
The clinician would definitely not make this switch if the test
results were negative and the test had a high negative predictive
value, because a negative test would mean that aspergillosis was
very unlikely. If the test results were positive and the test had
a high positive predictive value, the clinician might feel justified
in switching to or adding an echinocandin to the regimen be-
cause the odds were high that the patient had aspergillosis.
Patients with an intermediate pretest probability of disease
might include allogeneic bone marrow transplant recipients or
relapsed leukemic patients with new fever, recently initiated
antibacterial therapy, and chest CT that showed no pulmonary
infiltrate. The clinical question in this case is whether empirical
antifungal therapy should be started without waiting for a re-
sponse to antibacterial therapy. A negative test result could not
be used to decide whether to start or stop empirical antifungal
therapy, irrespective of the positive and negative predictive
value, because the test detects only aspergillosis and not can-
didiasis or other deep mycoses. On the other hand, a positive
test result would support a clinical decision to start antifungal
therapy with an agent that includes activity against Aspergillus,
but only if the positive predictive value were very high, that is,
the odds highly favored that all positive test results meant as-
pergillosis. Otherwise, too many patients would receive un-
necessary antifungal therapy.
In the case of patients with a low pretest probability of dis-
ease, such as a neutropenic, recently febrile autologous he-
matopoietic stem cell transplant recipient, the clinical question
might be whether a positive test can be used as a reason to
simply repeat the test, to admit the patient to the hospital, or
to obtain a high-resolution CT. The clinician could use a pos-
itive test result to make this decision if the negative predictive
value were high, even if the positive predictive value were low,
because the consequences of a false-positive result are modest.
At worst, a false-positive result would lead to unnecessary ra-
diological studies or hospital admission. A high negative pre-
dictive value is highly desirable in this clinical setting because
clinicians have to trust a negative test result to correctly exclude
patients who have early invasive aspergillosis.
Variability of results. Many variables determine how the
Aspergillus galactomannan test performs. Verweij et al. [3]
found 25% variability in assay titers between the 6 hospitals in
their study. This level of variability is a significant concern if
the test is going to be widely used as a part of the standard
diagnostic workup in multicenter clinical studies. Batch-by-
batch variability within individual centers has been reported
but appears to be less prevalent than variability between centers.
The use of prior triazole prophylaxis is an additional variable
to consider, because this has been shown to delay the time to
antigen positivity in both animal and clinical models [4].
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Sequential testing. Sequential galactomannan tests that
show repeated positive results, particularly with a rising titer,
have been advocated to increase the positive predictive value.
The time required to obtain additional tests inserts an unwel-
come delay into the clinical decision-making process. Published
studies do not make it clear how long one must wait to repeat
a test after obtaining a positive result but do indicate that a
new specimen is required. Repeating a test that yielded a pos-
itive result on the same specimen will usually produce the same
result.
Analysis of the published Aspergillus galactomannan ELISA
data indicates that no single interpretation applies to all pa-
tients. For patients at high risk of having invasive aspergillosis,
obtaining 2 consecutive positive test results offers strong sup-
port for the diagnosis. The test appears insensitive in early
disease and may not affect the use of empirical therapy. The
test may prove useful in antifungal trials as a criterion for
probable invasive aspergillosis, as has been proposed [5], and
should be evaluated in that setting.
USE OF HISTORICAL CONTROLS IN
ANTIFUNGAL THERAPY TRIALS
Use of historical control data for registration of antifungal
agents has been common in the past. For example, approvals
of azole drugs for treatment of blastomycosis, histoplasmosis,
and coccidioidomycosis were based on open-label, dose-finding
studies that compared results with published studies of am-
photericin B or no treatment. The lipid formulations of am-
photericin B were approved for the treatment of aspergillosis
in patients who were intolerant of approved drugs or whose
disease was refractory to prior therapy, and results were com-
pared with historical controls. However, conclusions based on
historical control data are known to be fallible in assessing
treatment efficacy because of the confounding effects of poor
data quality, variation in patient selection, and outcome eval-
uation bias [6, 7]. In addition, unmeasured confounders are
problematic. The Forum endorsed the criteria proposed by Rex
et al. [6] for good historical controls: clear and detailed inclu-
sion and exclusion criteria, scoring of outcomes by a panel of
blinded reviewers, use of objective and consistent definitions
of outcome appropriate for the patient population, use of con-
temporaneous patients, and analysis using both a cohort design
and a matched case-control design. Additional approaches that
further enhance the ability to interpret the results of historical
controls include distinguishing between enrollment in a salvage
trial for clinical failure versus for drug intolerance, prospective
collection of adequate data by use of better-designed case report
forms, and the availability of large and detailed reference da-
tabases from previous trials. Establishing databases with results
of prior trials would facilitate use of historical controls. How-
ever, the 2 major impediments to this approach are changes in
medical practice over time and the commercial reality that the
results of each trial belong to the company that funded it.
Historical controls in trials of therapy for invasive asper-
gillosis. The concerns about historical controls are particu-
larly pertinent in light of the fact that a new echinocandin,
caspofungin, was recently licensed by the US Food and Drug
Administration (FDA) solely on the basis of a comparison of
patients receiving caspofungin salvage treatment for aspergil-
losis and contemporaneous historical controls given ampho-
tericin B. Despite FDA approval, some clinicians have expressed
a reluctance to accept that caspofungin has demonstrated suf-
ficient clinical efficacy in treating aspergillosis, given that the
noncomparative study involved only 63 cases. In addition, the
FDA advisory committee had some reservations about the man-
ner in which the caspofungin data had been analyzed to draw
detailed conclusions about the efficacy of the drug, rather than
simply to observe the differences in outcomes between the
caspofungin salvage group and the amphotericin B historical
controls. The consensus at the Forum was that a randomized,
double-blinded comparison should be the goal in the future
and that acceptance of historical controls to license a drug sets
an unwelcome precedent.
Historical controls in trials of therapy for endemic myco-
ses. Unlike the population with invasive aspergillosis, non-
AIDS patients with selected endemic mycoses—for example,
blastomycosis, histoplasmosis, and coccidioidomycosis—differ
little from those of 50 years ago. Case definitions have been
relatively standardized. Diagnosis of these diseases is relatively
straightforward in comparison with aspergillosis, and there is
little need for the development of new surrogate markers.
Therefore, the use of historical controls may still be a valid
approach for certain populations of patients entered into trials
of new antifungal agents for endemic mycoses.
THE ROLE OF COOPERATIVE GROUPS IN THE
MANAGEMENT OF ANTIFUNGAL CLINICAL
TRIALS
Study groups dedicated to the improvement of trial design and
interdisciplinary cooperation have advanced the management
of antifungal clinical trials significantly in recent years. The
groups that perhaps have made the greatest contributions to
these advances include the Mycoses Study Group of the Na-
tional Institutes of Health and the Invasive Fungal Infections
Group (IFIG) of the European Organization for Research on
Treatment of Cancer (EORTC).
The Mycoses Study Group was established in 1978 under the
auspices of the National Institute of Allergy and Infectious
Diseases. The Bacteriology and Mycoses Study Group
(BAMSG), as is it now known, consists of experienced inves-
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tigators at 150 academic medical centers across the United
States. BAMSG is the prototype of a group that has successfully
bridged the gap between academia, federal government, and
industry. It has initiated 52 large-scale multicenter trials and
completed 36 of these trials.
IFIG, established in 1991, has conducted a number of large-
scale clinical studies of new antifungal agents, including the
voriconazole and liposomal amphotericin B (AmBisome; Fu-
jisawa Healthcare) phase III invasive aspergillosis studies. In
addition to IFIG, the EORTC has an active Antimicrobial Ther-
apy Group, which has led the way in the development of trials
of empirical therapy for the management of febrile neutropenic
patients since its inception in 1975. In the future, it is possible
that the 2 complementary EORTC groups may merge, but in
the meantime, both groups are looking for further opportu-
nities to collaborate, both within the EORTC and externally
with groups such as BAMSG.
Disadvantages. Although the advantages of cooperative
groups undoubtedly outweigh the disadvantages, there are a
number of limitations. Increasingly complex regulatory issues
about patient-oriented research necessitate close scrutiny by all
involved parties concerning study design, content of informed
consent, and institutional review board documents. Conse-
quently, the layers of administrative processing of concepts and
protocols can result, at times, in slow initiation of BAMSG
studies. This process may be a barrier to cooperation with
pharmaceutical companies, which must find the elusive com-
promise between running a high-quality study and completing
it in a timely and cost-effective manner.
Data sharing between industry and clinical trial groups can
be a source of conflict. Because the pharmaceutical industry
often files the Investigational New Drug Application with the
US FDA and European regulatory agencies, the responsibility
for collecting, verifying, and maintaining the confidentiality of
the case reports for many studies lies with the pharmaceutical
company sponsoring the drug. The reporting of safety problems
and final analysis of the data in the New Drug Application are
also the responsibility of the pharmaceutical company. The
clinical trial group needs access to sufficient data to make their
own analysis. The process and depth of data sharing vary with
the study but require the pharmaceutical company to provide
time, expense, and willingness to cooperate. Without mutual
trust and effort on both sides, the clinical trial group may be
asked simply to endorse data analysis provided by industry.
Advantages. Cooperative groups, such as EORTC and
BAMSG, offer several major advantages to the evaluation of
new drugs. In particular, each group offers a large pool of
investigators and study centers with validated experience and
productivity. These groups also have the facilities to run large,
statistically well-powered studies. Many recently published an-
tifungal studies have had insufficient power to be of any clinical
value. Such studies represent an inefficient use of valuable re-
sources. BAMSG and IFIG also offer specialized expertise in
clinical and laboratory mycology, particularly in the areas of
study design and independent data analysis and interpretation.
They also play a pivotal role in the training and development
of new clinical researchers.
Maintaining neutrality and impartiality is a key to the success
of cooperative groups. The structure and open financial ar-
rangements of BAMSG and IFIG, as well as the open discussions
they initiate, ensure that personal biases and personal aggran-
dizement are minimized.
Cooperative groups can be instrumental in helping to move
a study forward for publication. Authorship disputes are an
increasingly common problem in multicenter trials. An estab-
lished procedure, agreed upon before a study, for recognizing
individual contributions can minimize such problems in a study
group. The presence of writing committees that offer peer re-
view further enhances the manuscript development process.
Cooperative groups such as EORTC and BAMSG can add
value to industry trials of new antifungals by initiating concepts
or suggesting improvements in trial design, offering an inde-
pendent analysis of drugs across the antifungal field, providing
a strategic, long-term view of needs within the field, and bring-
ing to industry forward-thinking concepts for new trials. Cut-
ting-edge trials should be the top priority for large clinical trial
groups. Trial groups within the EORTC other than IFIG can
be a valuable resource to the IFIG by drawing on their expe-
rience with other classes of drugs. However, these benefits to
antifungal trials depend critically on successful interactions be-
tween the investigators, the pharmaceutical industry, and reg-
ulatory agencies. Discussion must begin early during trial design
for the process to benefit from the trial group’s expertise. Fre-
quent investigator meetings can speed trial development, solve
problems during study execution, and create harmony. Fur-
thermore, maintaining morale among the clinical research
nurses and coordinators at individual sites through regular
communication of study progress is vital to the overall success
of the venture.
Clinical trial groups should consider taking on the broader
mandate of holding workshops on study design or construction
of guidelines. Representatives from industry, regulatory agen-
cies, and the practice community can add important perspec-
tives. Better lines of communication and better antifungal drugs
are a shared goal.
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